^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma

Excerpt:
Overexpression of the CSC markers CD133 and CD90 in HCC was associated with poorer response to sorafenib.
DOI:
10.5009/gnl18345